Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of cholangiocarcinoma for each country, as well as annualized case counts projected to the national population.
In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s cholangiocarcinoma forecast will answer the following questions:
In developing countries, what impact will economic growth and development have on the number of people diagnosed with cholangiocarcinoma each year?
Of all people diagnosed with cholangiocarcinoma, how many in each of the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of cholangiocarcinoma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
Joy (Hongjin) Xu, M.P.H., is an associate epidemiologist at Clarivate. She has worked in multiple therapy areas but has a particular interest in cardiovascular epidemiology, autoimmune epidemiology, and data analytics. Ms. Xu holds a master’s degree in public health from Boston University and a bachelor’s degree in clinical medicine from Central South University in China.
Stephanie Niquita Phankon
Stephanie Niquita Phankon, M.B.B.S., M.P.H., Manager, Epidemiology. Ms. Phankon’s expertise is in autoimmune and inflammatory diseases and hematological malignancies. She holds a master’s in public health specializing in epidemiology from TISS in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China. She has been trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects.